ReviewMedGenMed : Medscape general medicine2005
Thyrotoxic atrial fibrillation.
Review in MedGenMed : Medscape general medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Therapeutic Plasma Exchange in Refractory Atrial Fibrillation Secondary to a Thyroid Storm.Cureus · 2023Article
- Cardiovascular Manifestations in Hyperthyroidism: A Cross-Sectional Study in a Tertiary Care Hospital in South India.Cureus · 2022Article
- Article
- ECG changes in patients with primary hyperthyroidism.The Pan African medical journal · 2018Article
- Cardiac hypertrophy and thyroid hormone signaling.Heart failure reviews · 2010Review
- Thyroid hormone predisposes rabbits to atrial arrhythmias by shortening monophasic action period and effective refractory period: results from an in vivo study.Journal of endocrinological investigation · 2009Article
- New onset thyrotoxicosis presenting as vomiting, abdominal pain and transaminitis in the emergency department.The western journal of emergency medicine · 2007Article
- Atrial fibrillation and hyperthyroidism: A literature review.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation is the most common cardiac complication of hyperthyroidism and occurs in 15% of patients with hyperthyroidism. It is associated with a higher risk of thromboembolism that often involves the central nervous system. Oral anticoagulation is important in the majority of these patients to prevent thromboembolic complications. These patients require adjustment in the dose of various rate-controlling agents because of increased clearance associated with hyperthyroidism and a decrease in warfarin dosage because of increased clearance of vitamin K-dependent clotting factors. The management of thyrotoxic atrial fibrillation is summarized in this clinical review.
Indexed as
Identifiers
16369379PMC1681414W177789772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.